Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
ANKRD55 is a key regulator of T cell inflammation in multiple sclerosis
Chuyu Wu, Meiling Jiang, Xue Yang, Yixuan Liu, Bin Huang, Yi Guo, Runjing Cao, Zhihui Cui, Guozhen Deng, Weiyan Wang, Mengdi Guo, Zhiyong Lin, Jiahui Fan, Lin-ming Zhang, Lorenzo Di Cesare Mannelli, Tao Pang, Chenhui Wang, Cun-Jin Zhang
Chuyu Wu, Meiling Jiang, Xue Yang, Yixuan Liu, Bin Huang, Yi Guo, Runjing Cao, Zhihui Cui, Guozhen Deng, Weiyan Wang, Mengdi Guo, Zhiyong Lin, Jiahui Fan, Lin-ming Zhang, Lorenzo Di Cesare Mannelli, Tao Pang, Chenhui Wang, Cun-Jin Zhang
View: Text | PDF
Research Article Autoimmunity Immunology

ANKRD55 is a key regulator of T cell inflammation in multiple sclerosis

  • Text
  • PDF
Abstract

Multiple sclerosis (MS) is a progressive, chronic, and highly disabling neuroinflammatory disorder characterized by demyelination and T cell–driven inflammation. Pathogenic T cells play a central role in MS, but effective therapeutic targeting remains challenging. Here, we identified ankyrin repeat domain–containing protein 55 (ANKRD55) as a key regulator of T cell function by single-cell transcriptomic analysis of cerebrospinal fluid and blood from MS patients. ANKRD55 was predominantly expressed in CD4+ T cells in both compartments. Genetic ablation of Ankrd55 led to a robustly reduced disease severity and neuroinflammation in experimental autoimmune encephalomyelitis (EAE), a widely used animal model for MS. Furthermore, T cell–specific deficiency of Ankrd55 significantly impaired Th1 polarization and Th17 differentiation, reducing EAE pathogenicity. Mechanistically, we found that Ankrd55 deficiency disrupted T cell receptor (TCR) signaling integrity. We demonstrated that ANKRD55 regulates the formation of the immune synapse, an essential prerequisite for TCR activation, by interacting with subunits of the chaperonin-containing TCP1 (CCT) complex and modulating its activity, enhancing its assembly by competing with CCT5 for binding to TCP1, CCT3, and CCT6. This facilitates proper microtubule organization and TCR activation. These findings establish ANKRD55 as a critical regulator of TCR signaling and highlight its therapeutic potential in pathogenic T cell–driven autoimmune diseases.

Authors

Chuyu Wu, Meiling Jiang, Xue Yang, Yixuan Liu, Bin Huang, Yi Guo, Runjing Cao, Zhihui Cui, Guozhen Deng, Weiyan Wang, Mengdi Guo, Zhiyong Lin, Jiahui Fan, Lin-ming Zhang, Lorenzo Di Cesare Mannelli, Tao Pang, Chenhui Wang, Cun-Jin Zhang

×

Figure 4

Genetic deletion of Ankrd55 in T cells protects from both active and Th1/Th17-mediated EAE.

Options: View larger image (or click on image) Download as PowerPoint
Genetic deletion of Ankrd55 in T cells protects from both active and Th1...
(A) Immunoblot analysis of ANKRD55 protein expression in CD4+ T cells from Ankrd55fl/fl mice and Ankrd55fl/fl LCKCre mice. (B) Mean clinical score of EAE in Ankrd55fl/fl mice and Ankrd55fl/fl LCKCre mice (n = 9 or 10 mice per group) induced by active immunization with MOG35–55. (C and D) Flow cytometry analysis of infiltrated immune cell in the brain at the peak of EAE disease in Ankrd55fl/fl mice and Ankrd55fl/fl LCKCre mice, including CD4+ T cells, CD8+ T cells, B cells, neutrophils, and monocytes. Data are presented as a summary plot of absolute cell counts (C) and a representative plot (D). (E) RT-qPCR analysis of inflammatory gene expression in the spinal cord during peak disease in Ankrd55fl/fl mice and Ankrd55fl/fl LCKCre mice. (F) Representative histological images of spinal cord sections from Ankrd55fl/fl and Ankrd55fl/fl LckCre mice at peak disease. LFB, Luxol fast blue. (G) Representative immunofluorescence staining of spinal cord sections from Ankrd55fl/fl and Ankrd55fl/fl LckCre mice at the peak of EAE. Sections were stained with antibodies against CD4, Ki67, and with DAPI. For quantification, 3 fields with evident immune cell infiltration were captured per mouse, and the percentage of Ki67+ cells among CD4+ T cells was calculated (n = 4 mice per group). Scale bars: 5 μm. (H) Schematic representation of the experiments in I and J. (I and J) Mean clinical score of EAE mice (n = 9 or 10 mice per group) induced by adoptive transfer of MOG-reactive Th1 (I) and Th17 (J) cells. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, based on unpaired, 2-tailed t test (C, E, and G) or 2-way ANOVA with Tukey’s multiple-comparison test (B, I, and I). Data are shown as mean ± SEM.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts